Paper
Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.
Published Jul 15, 2012 · J. Mun, A. Jabbar, N. Devi
Bioorganic & medicinal chemistry
Q2 SJR score
30
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
The 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide) can be modified to improve its pharmacological properties and potential as a cancer therapeutic.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Small molecules designed to inhibit the HIF-1 signaling pathway show promising potential for treating malignant behavior and therapeutic resistance in solid tumors.
2011·49citations·S. Mooring et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.
Sulfonamides show potential as a new scaffold for hypoxia inducible factor pathway inhibitors, potentially offering a new treatment option for cancer patients.
2011·39citations·Chalet Tan et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
HIF-1 contributes to cancer progression through its role in adaptive responses to reduced oxygen availability, and its inhibitors show anticancer effects in mouse models of human cancer.
2010·1677citations·G. Semenza·Oncogene
Oncogene
Identification of a Novel Small Molecule HIF-1α Translation Inhibitor
KC7F2 is a potent HIF-1 pathway inhibitor with potential as a cancer therapy agent, inhibiting transcription in various tumor types and exhibiting enhanced cytotoxicity under hypoxia.
2009·97citations·T. Narita et al.·Clinical Cancer Research
Clinical Cancer Research
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment.
HRE-IL-2-modified cytotoxic T cells can effectively treat human tumors in hypoxic environments, increasing tumor regression and overall survival.
2008·51citations·Hongsung Kim et al.·Molecular therapy : the journal of the American Society of Gene Therapy
Molecular therapy : the journal of the American Society of Gene Therapy
Citations
Improving the therapeutic window of anticancer agents by β-cyclodextrin encapsulation: Experimental and theoretical insights
-cyclodextrin complexation improves the solubility and anticancer therapeutic efficacy of MNC, a potent 3-nitro-2H-chromene derivative, for clinical translation.
2024·1citation·Nilima Priyadarsini Mishra et al.·Journal of Molecular Liquids
Journal of Molecular Liquids
A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy
The iPMP method effectively predicts clinical outcomes of immunotherapy in melanoma and non-small cell lung cancer by identifying significant mutation perturbation pathways.
2022·10citations·Xiangmei Li et al.·Briefings in bioinformatics
Briefings in bioinformatics
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth
Targeting hypoxia-induced P4HA1 and P4HA2 expression with KCN1 effectively inhibits primary and metastatic uveal melanoma growth and extends animal survival without overt side effects.
2021·17citations·Š. Kaluz et al.·Oncogene
Oncogene
Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway
HIF-1_H subtypes of prostate cancer have greater immune cell infiltration and better survival prognosis, making them more responsive to immunotherapy and guiding personalized treatment for prostate cancer patients.
2020·11citations·Jukun Song et al.·Frontiers in Oncology
Frontiers in Oncology
Synthesis and antiproliferative activity of new 2-glyco-3-nitro-2H-chromenes.
New 2-glyco-3-nitro-2H-chromenes show low micromolar antiproliferative activity against human solid tumor cell lines, with some showing more effectiveness than standard reference compounds.
2019·16citations·V. Luque-Agudo et al.·Bioorganic chemistry
Bioorganic chemistry
Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy.
Small molecules targeting HIF-1 have the potential to develop as novel anti-cancer therapies by blocking its protein-protein interactions and regulating various cancer processes.
2019·32citations·Jia Li et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Novel Hypoxia-Inducible Factor 1α (HIF-1α) Inhibitors for Angiogenesis-Related Ocular Diseases: Discovery of a Novel Scaffold via Ring-Truncation Strategy.
Ring-truncated deguelin analogs show potential as a novel scaffold for HIF-1 inhibitors, potentially improving treatment of angiogenesis-related ocular diseases.
2018·28citations·Hongchan An et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Hypoxia‐inducible factor‐1 (HIF‐1) inhibitors from the last decade (2007 to 2016): A “structure–activity relationship” perspective
HIF-1 inhibitors show promise in cancer drug development, potentially increasing patient response to chemotherapy and radiotherapy and improving survival rates.
2018·86citations·D. Bhattarai et al.·Medicinal Research Reviews
Medicinal Research Reviews
Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells
Montelukast shows potential as a novel prostate cancer treatment by decreasing HIF-1 protein translation and inhibiting prostate cancer cell proliferation.
2018·13citations·C. Tang et al.·Cancer Biology & Therapy
Cancer Biology & Therapy